New vaccine platform invented by Mayo enters COVID-19 clinical trial,

In contrast to replication-defective vaccines, the single-cycle vector amplifies immune response potential based on preclinical trials. “The single-cycle …, In contrast to replication-defective vaccines, the single-cycle vector amplifies immune response potential based on preclinical trials. “The single-cycle …, Read More

Scroll to Top